Polymorphisms in SREBF1 and SREBF2, two antipsychotic-activated transcription factors controlling cellular lipogenesis, are associated with schizophrenia in German and Scandinavian samples

Molecular Psychiatry

Volumn 15, Issue 5, 2010, Pages 463-472

  Le Hellard, S ^a,b   Muhleisen T W ^c   Djurovic, S ^d,e   Ferno J ^a,b   Ouriaghi, Z ^c   Mattheisen, M ^c   Vasilescu, C ^c   Raeder, M B ^a,b   Hansen, T ^f   Strohmaier, J ^g   Georgi, A ^g   Brockschmidt, F F ^c   Melle, I ^d,e   Nenadic, I ^h   Sauer, H ^h   Rietschel, M ^g   Nothen M M ^c   Werge, T ^f   Andreassen, O A ^d,e   Cichon, S ^c   Steen, V M ^a,b   more..

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BONN   (Germany)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f Sct Hans Hospital   (Denmark)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

17p; 22q; Functional convergent genomics; Lipids; Myelin

Indexed keywords

GENOMIC DNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

ADULT; ARTICLE; CELL METABOLISM; CONTROLLED STUDY; DENMARK; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; GENE; GENE FUNCTION; GENE LOCATION; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC SUSCEPTIBILITY; GENOTYPE; GERMANY; HAPLOTYPE; HUMAN; LIPOGENESIS; MAJOR CLINICAL STUDY; MALE; MARKER GENE; NORWAY; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SREBF 1 GENE; SREBF 2 GENE;

EID: 77951878950     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2008.110     Document Type: Article

References (63)

1. Carter CJ. Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophr Res 2006; 86: 1-14.
2. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR et al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 2003; 60: 443-456. (Pubitemid 36539053)
3. Karoutzou G, Emrich HM, Dietrich DE. The myelin-pathogenesis puzzle in schizophrenia: a literature review. Mol Psychiatry 2008; 13: 245-260. (Pubitemid 351272657)
4. Le-Niculescu H, Balaraman Y, Patel S, Tan J, Sidhu K, Jerome RE et al. Towards understanding the schizophrenia code: an expanded convergent functional genomics approach. Am J Med Genet B Neuropsychiatr Genet 2007; 144: 129-158. (Pubitemid 46606639)
5. Ferno J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ et al. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics 2005; 5: 298-304. (Pubitemid 41486229)
6. Ferno J, Skrede S, Vik-Mo AO, Ha?vik B, Steen VM. Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci 2006; 7: 69. (Pubitemid 44741152)
7. Edwards PA, Tabor D, Kast HR, Venkateswaran A. Regulation of gene expression by SREBP and SCAP. Biochim Biophys Acta 2000; 1529: 103-113.
8. Horton JD, Shimomura I, Brown MS, Hammer RE, Goldstein JL, Shimano H. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J Clin Invest 1998; 101: 2331-2339. (Pubitemid 28270427)
9. Garver DL, Holcomb JA, Christensen JD. Compromised myelin integrity during psychosis with repair during remission in drug-responding schizophrenia. Int J Neuropsychopharmacol 2008; 11: 49-61.
10. Dietschy JM, Turley SD. Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 2004; 45: 1375-1397.
11. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 1997; 99: 846-854. (Pubitemid 27123620)
12. American Psychiatric Association, Committee on Nomenclature and Statistics. Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association: Washington, 1994.
13. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. Patient ed. Biometrics Research Department, New York State Psychiatric Institute: New York, 1997.
14. Farmer AE, Wessely S, Castle D, McGuffin P. Methodological issues in using a polydiagnostic approach to define psychotic illness. Br J Psychiatry 1992; 161: 824-830.
15. Leckman JF, Sholomskas D, Thompson WD, Belanger A, Weissman MM. Best estimate of lifetime psychiatric diagnosis: a methodological study. Arch Gen Psychiatry 1982; 39: 879-883. (Pubitemid 12042853)
16. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res 1988; 16: 1215.
17. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265. (Pubitemid 40202029)
18. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-2229. (Pubitemid 34680308)
19. Zogopoulos G, Ha KC, Naqib F, Moore S, Kim H, Montpetit A et al. Germ-line DNA copy number variation frequencies in a large North American population. Hum Genet 2007; 122: 345-353. (Pubitemid 47616542)
20. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y et al. Detection of large-scale variation in the human genome. Nat Genet 2004; 36: 949-951. (Pubitemid 39167488)
21. Colella S, Yau C, Taylor JM, Mirza G, Butler H, Clouston P et al. QuantiSNP: an Objective Bayes Hidden-Markov Model to detect and accurately map copy number variation using SNP genotyping data. Nucl Acid Res 2007; 35: 2013-2025. (Pubitemid 47061667)
22. Hansen T, Olsen L, Lindow M, Jakobsen KD, Ullum H, Jonsson E et al. Brain expressed microRNAs implicated in schizophrenia etiology. PLoS One 2007; 2: e873. (Pubitemid 351425674)
23. Joober R, Benkelfat C, Toulouse A, Lafrenière RG, Lal S, Ajroud S et al. Analysis of 14 CAG repeat-containing genes in schizophrenia. Am J Med Genet 1999; 88: 694-699.
24. Eberlé D, Clément K, Meyre D, Sahbatou M, Vaxillaire M, Le Gall A et al. SREBF-1 gene polymorphisms are associated with obesity and type 2 diabetes in French obese and diabetic cohorts. Diabetes 2004; 53: 2153-2157. (Pubitemid 38970769)
25. Rios DL, Vargas AF, Torres MR, Zago AJ, Callegari-Jacques SM, Hutz MH. Interaction between SREBP-1a and APOB polymorphisms influences total and low-density lipoprotein cholesterol levels in patients with coronary artery disease. Clin Genet 2003; 63: 380-385.
26. Salek L, Lutucuta S, Ballantyne CM, Gotto Jr AM, Marian AJ. Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. J Mol Med 2002; 80: 737-744.
27. Condra JA, Neibergs H, Wei W, Brennan MD. Evidence for two schizophrenia susceptibility genes on chromosome 22q13. Psychiatry Genet 2007; 17: 292-298. (Pubitemid 47345751)
28. Miyakawa T, Sumiyoshi S, Deshimaru M, Suzuki T, Tomonari H. Electron microscopic study on schizophrenia. Mechanism of pathological changes. Acta Neuropathol 1972; 20: 67-77.
29. Uranova N, Orlovskaya D, Vikhreva O, Zimina I, Kolomeets N, Vostrikov V et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull 2001; 55: 597-610. (Pubitemid 32888378)
30. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley neuropathology consortium. Schizophr Res 2004; 67: 269-275.
31. Buchsbaum MS, Tang CY, Peled S, Gudbjartsson H, Lu D, Hazlett EA et al. MRI white matter diffusion anisotropy and PET metabolic rate in schizophrenia. Neuroreport 1998; 9: 425-430. (Pubitemid 28109200)
32. Kanaan RA, Kim JS, Kaufmann WE, Pearlson GD, Barker GJ, McGuire PK. Diffusion tensor imaging in schizophrenia. Biol Psychiatry 2005; 58: 921-929.
33. Kubicki M, McCarley RW, Shenton ME. Evidence for white matter abnormalities in schizophrenia. Curr Opin Psychiatry 2005; 18: 121-134. (Pubitemid 40824443)
34. Lim KO, Adalsteinsson E, Spielman D, Sullivan EV, Rosenbloom MJ, Pfefferbaum A. Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. Arch Gen Psychiatry 1998; 55: 346-352. (Pubitemid 28173624)
35. van Haren NE, Hulshoff Pol HE, Schnack HG, Cahn W, Mandl RC, Collins DL et al. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsycho-pharmacology 2007; 32: 2057-2066. (Pubitemid 47417696)
36. Molina V, Reig S, Sanz J, Palomo T, Benito C, Sánchez J et al. Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. Schizophr Res 2005; 80: 61-71. (Pubitemid 41587464)
37. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003; 362: 798-805. (Pubitemid 37093922)
38. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD et al. Genome-wide expression analysis reveals dysregulation of myeli-nation-related genes in chronic schizophrenia. Proc Natl Acad Sci 2001; 98: 4746-4751. (Pubitemid 32295047)
39. Katsel P, Davis KL, Haroutunian V. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophr Res 2005; 79: 157-173. (Pubitemid 41457256)
40. Aston C, Jiang L, Sokolov BP. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res 2004; 77: 858-866. (Pubitemid 39187068)
41. Aston C, Jiang L, Sokolov BP. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol Psychiatry 2005; 10: 309-322. (Pubitemid 40432684)
42. de Graaf-Peters VB, Hadders-Algra M. Ontogeny of the human central nervous system: what is happening when? Early Hum Dev 2006; 82: 257-266.
43. Paus T, Zijdenbos A, Worsley K, Collins DL, Blumenthal J, Giedd JN et al. Structural maturation of neural pathways in children and adolescents: in vivo study. Science 1999; 283: 1908-1911. (Pubitemid 129504141)
44. Giedd JN, Blumenthal J, Jeffries NO, Castellanos FX, Liu H, Zijdenbos A et al. Brain development during childhood and adolescence: a longitudinal MRI study. Nat Neurosci 1999; 2: 861-863. (Pubitemid 30602596)
45. Bartzokis G, Beckson M, Lu PH, Nuechterlein KH, Edwards N, Mintz J. Age-related changes in frontal and temporal lobe volumes in men: a magnetic resonance imaging study. Arch Gen Psychiatry 2001; 58: 461-465. (Pubitemid 32411326)
46. Bartzokis G. Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation. Neuro-psychopharmacology 2002; 27: 672-683.
47. Saher G, Brügger B, Lappe-Siefke C, Möbius W, Tozawa R, Wehr MC et al. High cholesterol level is essential for myelin membrane growth. Nat Neurosci 2005; 8: 468-475. (Pubitemid 41007564)
48. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-1131.
49. Loewen CJ, Levine TP. Cholesterol homeostasis: not until the SCAP lady INSIGs. Curr Biol 2002; 12: R779-R781.
50. Leblanc SE, Srinivasan R, Ferri C, Mager GM, Gillian-Daniel AL, Wrabetz L et al. Regulation of cholesterol/lipid biosynthetic genes by Egr2/Krox20 during peripheral nerve myelination. J Neuro-chem 2005; 93: 737-748. (Pubitemid 40617633)
51. Verheijen MH, Chrast R, Burrola P, Lemke G. Local regulation of fat metabolism in peripheral nerves. Genes Dev 2003; 17: 2450-2464. (Pubitemid 37214792)
52. Sokolov BP. Oligodendroglial abnormalities in schizophrenia, mood disorders and substance abuse. Comorbidity, shared traits, or molecular phenocopies? Int J Neuropsychopharmacol 2007; 10: 547-555.
53. Le-Niculescu H, McFarland MJ, Ogden CA, Balaraman Y, Patel S, Ta n J et al. Phenomic, convergent functional genomic, and biomarker studies in a stress-reactive genetic animal model of bipolar disorder and co-morbid alcoholism. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 134-166. (Pubitemid 351355275)
54. Xiao L, Xu H, Zhang Y, Wei Z, He J, Jiang W et al. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol Psychiatry 2008; 13: 697-708. (Pubitemid 351861531)
55. Bartzokis G, Lu PH, Nuechterlein KH, Gitlin M, Doi C, Edwards N et al. Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia. Schizophr Res 2007; 93: 13-22. (Pubitemid 46830753)
56. Huang TL, Lu CY. Correlations between weight changes and lipid profile changes in schizophrenic patients after antipsychotics therapy. Chang Gung Med J 2007; 30: 26-32.
57. Procyshyn RM, Wasan KM, Thornton AE, Barr AM, Chen EY, Pomarol-Clotet E et al. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci 2007; 32: 331-338. (Pubitemid 47492758)
58. Raeder MB, Ferno J, Glambek M, Stansberg C, Steen VM. Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neurosci Lett 2006; 395: 185-190. (Pubitemid 43213141)
59. Raeder MB, Ferno J, Vik-Mo AO, Steen VM. SREBP activation by antipsychotic-and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects? Mol Cell Biochem 2006; 289: 167-173. (Pubitemid 44322486)
60. Vik-Mo AO, Birkenaes AB, Fernø J, Jonsdottir H, Andreassen OA, Steen VM. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Int J Neuropsychopharmacol 2008; 11: 679-684. (Pubitemid 351931824)
61. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007; 12: 707-747. (Pubitemid 47172693)
62. Le Hellard S, Theisen FM, Haberhausen M, Raeder MB, Fernø J, Gebhardt S et al. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?. Mol Psychiatry 2008; e-pub ahead of print: doi:10.1038.
63. Malhotra AK, Lencz T, Correll CU, Kane JM. Genomics and the future of pharmacotherapy in psychiatry. Int Rev Psychiatry 2007; 19: 523-530. (Pubitemid 47493739)